Evaluation: Novel Therapeutic Approaches to Alzheimer's Disease: A Focus on Immunotherapy

Submitted by Jack Attack on Thu, 05/14/2015 - 12:49pm

What best describes your current professional status? *

Private

Hospital

Academic

Other

What best describes your current professional status? Other

Please rate the extent to which the activity met the following objectives: *

Use the scale: 1=Poor, 2=Fair, 3=Good, 4=Very Good, 5=Excellent

	1	2	3	4	5
Discuss the importance of early detection and management of AD	Discuss the importance of early detection and management of AD - 1	Discuss the importance of early detection and management of AD - 2	Discuss the importance of early detection and management of AD - 3	Discuss the importance of early detection and management of AD - 4	Discuss the importance of early detection and management of AD - 5
Identify immunotherapies in development for the treatment of AD	Identify immunotherapies in development for the treatment of AD - 1	Identify immunotherapies in development for the treatment of AD - 2	Identify immunotherapies in development for the treatment of AD - 3	Identify immunotherapies in development for the treatment of AD - 4	Identify immunotherapies in development for the treatment of AD - 5
Analyze the use of biomarkers to identify patients with early-stage AD	Analyze the use of biomarkers to identify patients with early-stage AD - 1	Analyze the use of biomarkers to identify patients with early-stage AD - 2	Analyze the use of biomarkers to identify patients with early-stage AD - 3	Analyze the use of biomarkers to identify patients with early-stage AD - 4	Analyze the use of biomarkers to identify patients with early-stage AD - 5

Please indicate your familiarity with the following information PRIOR to attending this activity: *

Please use the scale: 1=Not at all familiar, 2=Somewhat familiar, 3=Familiar, 4=Very familiar, 5=Expert on this subject, 6=N/A for me

	1	2	3	4	5	6
The pivotal pathogenic AD pathway involving beta-secretase and gamma- secretase	The pivotal pathogenic AD pathway involving beta-secretase and gamma- secretase - 1	The pivotal pathogenic AD pathway involving beta-secretase and gamma- secretase - 2	The pivotal pathogenic AD pathway involving beta-secretase and gamma- secretase - 3	The pivotal pathogenic AD pathway involving beta-secretase and gamma- secretase - 4	The pivotal pathogenic AD pathway involving beta-secretase and gamma- secretase - 5	The pivotal pathogenic AD pathway involving beta-secretase and gamma- secretase - 6
The ongoing phase III trials of solanezumab, gantenerumab, and aducanumab and the ongoing phase II trials of crenezumab and BAN-2401	The ongoing phase III trials of solanezumab, gantenerumab, and aducanumab and the ongoing phase II trials of crenezumab and BAN-2401 - 1	The ongoing phase III trials of solanezumab, gantenerumab, and aducanumab and the ongoing phase II trials of crenezumab and BAN-2401 - 2	The ongoing phase III trials of solanezumab, gantenerumab, and aducanumab and the ongoing phase II trials of crenezumab and BAN-2401 - 3	The ongoing phase III trials of solanezumab, gantenerumab, and aducanumab and the ongoing phase II trials of crenezumab and BAN-2401 - 4	The ongoing phase III trials of solanezumab, gantenerumab, and aducanumab and the ongoing phase II trials of crenezumab and BAN-2401 - 5	The ongoing phase III trials of solanezumab, gantenerumab, and aducanumab and the ongoing phase II trials of crenezumab and BAN-2401 - 6
That the negative or marginal results from anti-amyloid trials to date may have been caused by wrong disease stage, a heterogeneous population, limited target engagement due to ARIA-related dose restrictions, and/or only a partial effect observed with monotherapy	That the negative or marginal results from anti-amyloid trials to date may have been caused by wrong disease stage, a heterogeneous population, limited target engagement due to ARIA-related dose restrictions, and/or only a partial effect observed with monotherapy - 1	That the negative or marginal results from anti-amyloid trials to date may have been caused by wrong disease stage, a heterogeneous population, limited target engagement due to ARIA-related dose restrictions, and/or only a partial effect observed with monotherapy - 2	That the negative or marginal results from anti-amyloid trials to date may have been caused by wrong disease stage, a heterogeneous population, limited target engagement due to ARIA-related dose restrictions, and/or only a partial effect observed with monotherapy - 3	That the negative or marginal results from anti-amyloid trials to date may have been caused by wrong disease stage, a heterogeneous population, limited target engagement due to ARIA-related dose restrictions, and/or only a partial effect observed with monotherapy - 4	That the negative or marginal results from anti-amyloid trials to date may have been caused by wrong disease stage, a heterogeneous population, limited target engagement due to ARIA-related dose restrictions, and/or only a partial effect observed with monotherapy - 5	That the negative or marginal results from anti-amyloid trials to date may have been caused by wrong disease stage, a heterogeneous population, limited target engagement due to ARIA-related dose restrictions, and/or only a partial effect observed with monotherapy - 6
Potential for combination therapy with secretase inhibitors, anti-amyloid antibodies, anti-tau agents, and neuroprotective drugs	Potential for combination therapy with secretase inhibitors, anti-amyloid antibodies, anti-tau agents, and neuroprotective drugs - 1	Potential for combination therapy with secretase inhibitors, anti-amyloid antibodies, anti-tau agents, and neuroprotective drugs - 2	Potential for combination therapy with secretase inhibitors, anti-amyloid antibodies, anti-tau agents, and neuroprotective drugs - 3	Potential for combination therapy with secretase inhibitors, anti-amyloid antibodies, anti-tau agents, and neuroprotective drugs - 4	Potential for combination therapy with secretase inhibitors, anti-amyloid antibodies, anti-tau agents, and neuroprotective drugs - 5	Potential for combination therapy with secretase inhibitors, anti-amyloid antibodies, anti-tau agents, and neuroprotective drugs - 6
That Alzheimer’s pathology, as defined by the presence of amyloid and tau on PET probably appears approximately 10 years before the illness	That Alzheimer’s pathology, as defined by the presence of amyloid and tau on PET probably appears approximately 10 years before the illness - 1	That Alzheimer’s pathology, as defined by the presence of amyloid and tau on PET probably appears approximately 10 years before the illness - 2	That Alzheimer’s pathology, as defined by the presence of amyloid and tau on PET probably appears approximately 10 years before the illness - 3	That Alzheimer’s pathology, as defined by the presence of amyloid and tau on PET probably appears approximately 10 years before the illness - 4	That Alzheimer’s pathology, as defined by the presence of amyloid and tau on PET probably appears approximately 10 years before the illness - 5	That Alzheimer’s pathology, as defined by the presence of amyloid and tau on PET probably appears approximately 10 years before the illness - 6
That tau PET shows the presence of pathology even in younger individuals and that in normal elderly, between the ages of 65 and 85 years, the presence of tau on PET imaging correlates with worse memory performance	That tau PET shows the presence of pathology even in younger individuals and that in normal elderly, between the ages of 65 and 85 years, the presence of tau on PET imaging correlates with worse memory performance - 1	That tau PET shows the presence of pathology even in younger individuals and that in normal elderly, between the ages of 65 and 85 years, the presence of tau on PET imaging correlates with worse memory performance - 2	That tau PET shows the presence of pathology even in younger individuals and that in normal elderly, between the ages of 65 and 85 years, the presence of tau on PET imaging correlates with worse memory performance - 3	That tau PET shows the presence of pathology even in younger individuals and that in normal elderly, between the ages of 65 and 85 years, the presence of tau on PET imaging correlates with worse memory performance - 4	That tau PET shows the presence of pathology even in younger individuals and that in normal elderly, between the ages of 65 and 85 years, the presence of tau on PET imaging correlates with worse memory performance - 5	That tau PET shows the presence of pathology even in younger individuals and that in normal elderly, between the ages of 65 and 85 years, the presence of tau on PET imaging correlates with worse memory performance - 6

Please indicate your familiarity with the following information AFTER attending this activity: *

Please use the scale: 1=Not at all familiar, 2=Somewhat familiar, 3=Familiar, 4=Very familiar, 5=Expert on this subject, 6=N/A for me

	1	2	3	4	5	6
The pivotal pathogenic AD pathway involving beta-secretase and gamma- secretase	The pivotal pathogenic AD pathway involving beta-secretase and gamma- secretase - 1	The pivotal pathogenic AD pathway involving beta-secretase and gamma- secretase - 2	The pivotal pathogenic AD pathway involving beta-secretase and gamma- secretase - 3	The pivotal pathogenic AD pathway involving beta-secretase and gamma- secretase - 4	The pivotal pathogenic AD pathway involving beta-secretase and gamma- secretase - 5	The pivotal pathogenic AD pathway involving beta-secretase and gamma- secretase - 6
The ongoing phase III trials of solanezumab, gantenerumab, and aducanumab and the ongoing phase II trials of crenezumab and BAN-2401	The ongoing phase III trials of solanezumab, gantenerumab, and aducanumab and the ongoing phase II trials of crenezumab and BAN-2401 - 1	The ongoing phase III trials of solanezumab, gantenerumab, and aducanumab and the ongoing phase II trials of crenezumab and BAN-2401 - 2	The ongoing phase III trials of solanezumab, gantenerumab, and aducanumab and the ongoing phase II trials of crenezumab and BAN-2401 - 3	The ongoing phase III trials of solanezumab, gantenerumab, and aducanumab and the ongoing phase II trials of crenezumab and BAN-2401 - 4	The ongoing phase III trials of solanezumab, gantenerumab, and aducanumab and the ongoing phase II trials of crenezumab and BAN-2401 - 5	The ongoing phase III trials of solanezumab, gantenerumab, and aducanumab and the ongoing phase II trials of crenezumab and BAN-2401 - 6
That the negative or marginal results from anti-amyloid trials to date may have been caused by wrong disease stage, a heterogeneous population, limited target engagement due to ARIA-related dose restrictions, and/or only a partial effect observed with monotherapy	That the negative or marginal results from anti-amyloid trials to date may have been caused by wrong disease stage, a heterogeneous population, limited target engagement due to ARIA-related dose restrictions, and/or only a partial effect observed with monotherapy - 1	That the negative or marginal results from anti-amyloid trials to date may have been caused by wrong disease stage, a heterogeneous population, limited target engagement due to ARIA-related dose restrictions, and/or only a partial effect observed with monotherapy - 2	That the negative or marginal results from anti-amyloid trials to date may have been caused by wrong disease stage, a heterogeneous population, limited target engagement due to ARIA-related dose restrictions, and/or only a partial effect observed with monotherapy - 3	That the negative or marginal results from anti-amyloid trials to date may have been caused by wrong disease stage, a heterogeneous population, limited target engagement due to ARIA-related dose restrictions, and/or only a partial effect observed with monotherapy - 4	That the negative or marginal results from anti-amyloid trials to date may have been caused by wrong disease stage, a heterogeneous population, limited target engagement due to ARIA-related dose restrictions, and/or only a partial effect observed with monotherapy - 5	That the negative or marginal results from anti-amyloid trials to date may have been caused by wrong disease stage, a heterogeneous population, limited target engagement due to ARIA-related dose restrictions, and/or only a partial effect observed with monotherapy - 6
Potential for combination therapy with secretase inhibitors, anti-amyloid antibodies, anti-tau agents, and neuroprotective drugs	Potential for combination therapy with secretase inhibitors, anti-amyloid antibodies, anti-tau agents, and neuroprotective drugs - 1	Potential for combination therapy with secretase inhibitors, anti-amyloid antibodies, anti-tau agents, and neuroprotective drugs - 2	Potential for combination therapy with secretase inhibitors, anti-amyloid antibodies, anti-tau agents, and neuroprotective drugs - 3	Potential for combination therapy with secretase inhibitors, anti-amyloid antibodies, anti-tau agents, and neuroprotective drugs - 4	Potential for combination therapy with secretase inhibitors, anti-amyloid antibodies, anti-tau agents, and neuroprotective drugs - 5	Potential for combination therapy with secretase inhibitors, anti-amyloid antibodies, anti-tau agents, and neuroprotective drugs - 6
That Alzheimer’s pathology, as defined by the presence of amyloid and tau on PET probably appears approximately 10 years before the illness	That Alzheimer’s pathology, as defined by the presence of amyloid and tau on PET probably appears approximately 10 years before the illness - 1	That Alzheimer’s pathology, as defined by the presence of amyloid and tau on PET probably appears approximately 10 years before the illness - 2	That Alzheimer’s pathology, as defined by the presence of amyloid and tau on PET probably appears approximately 10 years before the illness - 3	That Alzheimer’s pathology, as defined by the presence of amyloid and tau on PET probably appears approximately 10 years before the illness - 4	That Alzheimer’s pathology, as defined by the presence of amyloid and tau on PET probably appears approximately 10 years before the illness - 5	That Alzheimer’s pathology, as defined by the presence of amyloid and tau on PET probably appears approximately 10 years before the illness - 6
That tau PET shows the presence of pathology even in younger individuals and that in normal elderly, between the ages of 65 and 85 years, the presence of tau on PET imaging correlates with worse memory performance	That tau PET shows the presence of pathology even in younger individuals and that in normal elderly, between the ages of 65 and 85 years, the presence of tau on PET imaging correlates with worse memory performance - 1	That tau PET shows the presence of pathology even in younger individuals and that in normal elderly, between the ages of 65 and 85 years, the presence of tau on PET imaging correlates with worse memory performance - 2	That tau PET shows the presence of pathology even in younger individuals and that in normal elderly, between the ages of 65 and 85 years, the presence of tau on PET imaging correlates with worse memory performance - 3	That tau PET shows the presence of pathology even in younger individuals and that in normal elderly, between the ages of 65 and 85 years, the presence of tau on PET imaging correlates with worse memory performance - 4	That tau PET shows the presence of pathology even in younger individuals and that in normal elderly, between the ages of 65 and 85 years, the presence of tau on PET imaging correlates with worse memory performance - 5	That tau PET shows the presence of pathology even in younger individuals and that in normal elderly, between the ages of 65 and 85 years, the presence of tau on PET imaging correlates with worse memory performance - 6

How often do you CURRENTLY do each of the following? *

Please use the scale: 1=Never, 2=Not Often, 3=Sometimes, 4=Often, 5=Always, 6=N/A

	1	2	3	4	5	6
I stay up-to-date on the advances in biomarkers for the diagnosis of Alzheimer’s disease	I stay up-to-date on the advances in biomarkers for the diagnosis of Alzheimer’s disease - 1	I stay up-to-date on the advances in biomarkers for the diagnosis of Alzheimer’s disease - 2	I stay up-to-date on the advances in biomarkers for the diagnosis of Alzheimer’s disease - 3	I stay up-to-date on the advances in biomarkers for the diagnosis of Alzheimer’s disease - 4	I stay up-to-date on the advances in biomarkers for the diagnosis of Alzheimer’s disease - 5	I stay up-to-date on the advances in biomarkers for the diagnosis of Alzheimer’s disease - 6
I stay up-to-date on the research regarding combination treatment with both existing and emerging medications	I stay up-to-date on the research regarding combination treatment with both existing and emerging medications - 1	I stay up-to-date on the research regarding combination treatment with both existing and emerging medications - 2	I stay up-to-date on the research regarding combination treatment with both existing and emerging medications - 3	I stay up-to-date on the research regarding combination treatment with both existing and emerging medications - 4	I stay up-to-date on the research regarding combination treatment with both existing and emerging medications - 5	I stay up-to-date on the research regarding combination treatment with both existing and emerging medications - 6

How often do you PLAN TO do each of the following? *

Please use the scale: 1=Never, 2=Not Often, 3=Sometimes, 4=Often, 5=Always, 6=N/A

	1	2	3	4	5	6
I stay up-to-date on the advances in biomarkers for the diagnosis of Alzheimer’s disease	I stay up-to-date on the advances in biomarkers for the diagnosis of Alzheimer’s disease - 1	I stay up-to-date on the advances in biomarkers for the diagnosis of Alzheimer’s disease - 2	I stay up-to-date on the advances in biomarkers for the diagnosis of Alzheimer’s disease - 3	I stay up-to-date on the advances in biomarkers for the diagnosis of Alzheimer’s disease - 4	I stay up-to-date on the advances in biomarkers for the diagnosis of Alzheimer’s disease - 5	I stay up-to-date on the advances in biomarkers for the diagnosis of Alzheimer’s disease - 6
I stay up-to-date on the research regarding combination treatment with both existing and emerging medications	I stay up-to-date on the research regarding combination treatment with both existing and emerging medications - 1	I stay up-to-date on the research regarding combination treatment with both existing and emerging medications - 2	I stay up-to-date on the research regarding combination treatment with both existing and emerging medications - 3	I stay up-to-date on the research regarding combination treatment with both existing and emerging medications - 4	I stay up-to-date on the research regarding combination treatment with both existing and emerging medications - 5	I stay up-to-date on the research regarding combination treatment with both existing and emerging medications - 6

Please provide us with feedback regarding your experience at the activity: *

Please use the scale: 1=Strongly Disagree, 2=Disagree, 3=Neutral, 4=Agree, 5=Strongly Agree

	1	2	3	4	5
Overall, the activity met my learning needs	Overall, the activity met my learning needs - 1	Overall, the activity met my learning needs - 2	Overall, the activity met my learning needs - 3	Overall, the activity met my learning needs - 4	Overall, the activity met my learning needs - 5
The information presented was without promotional or commercial bias	The information presented was without promotional or commercial bias - 1	The information presented was without promotional or commercial bias - 2	The information presented was without promotional or commercial bias - 3	The information presented was without promotional or commercial bias - 4	The information presented was without promotional or commercial bias - 5
The information presented was scientifically rigorous and evidence based	The information presented was scientifically rigorous and evidence based - 1	The information presented was scientifically rigorous and evidence based - 2	The information presented was scientifically rigorous and evidence based - 3	The information presented was scientifically rigorous and evidence based - 4	The information presented was scientifically rigorous and evidence based - 5
The information presented provided appropriate and effective opportunities for active learning (discussion, Q&A)	The information presented provided appropriate and effective opportunities for active learning (discussion, Q&A) - 1	The information presented provided appropriate and effective opportunities for active learning (discussion, Q&A) - 2	The information presented provided appropriate and effective opportunities for active learning (discussion, Q&A) - 3	The information presented provided appropriate and effective opportunities for active learning (discussion, Q&A) - 4	The information presented provided appropriate and effective opportunities for active learning (discussion, Q&A) - 5
The information presented promoted improvements or quality in health care	The information presented promoted improvements or quality in health care - 1	The information presented promoted improvements or quality in health care - 2	The information presented promoted improvements or quality in health care - 3	The information presented promoted improvements or quality in health care - 4	The information presented promoted improvements or quality in health care - 5
The quality of the educational process was satisfactory and appropriate	The quality of the educational process was satisfactory and appropriate - 1	The quality of the educational process was satisfactory and appropriate - 2	The quality of the educational process was satisfactory and appropriate - 3	The quality of the educational process was satisfactory and appropriate - 4	The quality of the educational process was satisfactory and appropriate - 5
The information provided with regard to faculty relations met my needs for disclosure	The information provided with regard to faculty relations met my needs for disclosure - 1	The information provided with regard to faculty relations met my needs for disclosure - 2	The information provided with regard to faculty relations met my needs for disclosure - 3	The information provided with regard to faculty relations met my needs for disclosure - 4	The information provided with regard to faculty relations met my needs for disclosure - 5
The speakers were knowledgeable and presented the information clearly	The speakers were knowledgeable and presented the information clearly - 1	The speakers were knowledgeable and presented the information clearly - 2	The speakers were knowledgeable and presented the information clearly - 3	The speakers were knowledgeable and presented the information clearly - 4	The speakers were knowledgeable and presented the information clearly - 5
The format of the discussion was relevant and enhanced my knowledge of the subject	The format of the discussion was relevant and enhanced my knowledge of the subject - 1	The format of the discussion was relevant and enhanced my knowledge of the subject - 2	The format of the discussion was relevant and enhanced my knowledge of the subject - 3	The format of the discussion was relevant and enhanced my knowledge of the subject - 4	The format of the discussion was relevant and enhanced my knowledge of the subject - 5
The registration process for this meeting was efficient and professional	The registration process for this meeting was efficient and professional - 1	The registration process for this meeting was efficient and professional - 2	The registration process for this meeting was efficient and professional - 3	The registration process for this meeting was efficient and professional - 4	The registration process for this meeting was efficient and professional - 5

Please rate the faculty on his/her overall teaching ability and overall knowledge and level of expertise regarding the subject: *

Use the scale: 1=Poor, 2=Fair, 3=Good, 4=Very Good, 5=Excellent

	1	2	3	4	5
Paul S. Aisen, MD (Program Chair)	Paul S. Aisen, MD (Program Chair) - 1	Paul S. Aisen, MD (Program Chair) - 2	Paul S. Aisen, MD (Program Chair) - 3	Paul S. Aisen, MD (Program Chair) - 4	Paul S. Aisen, MD (Program Chair) - 5
Keith Johnson, MD	Keith Johnson, MD - 1	Keith Johnson, MD - 2	Keith Johnson, MD - 3	Keith Johnson, MD - 4	Keith Johnson, MD - 5
Stephen Salloway, MD, MS	Stephen Salloway, MD, MS - 1	Stephen Salloway, MD, MS - 2	Stephen Salloway, MD, MS - 3	Stephen Salloway, MD, MS - 4	Stephen Salloway, MD, MS - 5

This educational activity will result in a change in my practice behavior. *

Yes

N/A

If so, what will you change?

Based on your participation in this activity, choose the statement(s) that apply: *

I gained new strategies/skills/information that I can apply to my area of practice

I plan to implement new strategies/skills/information to my practice

I need more information before I can implement new strategies/skills/information in my practice.

This activity will not change my practice, as my current practice is consistent with the information presented.

This activity will not change my practice, as I do not agree with the information presented.

What barriers do you see regarding making a change in your practice?

Would you be willing to participate in a post activity follow-up survey? *

Yes

Do you wish to be notified by email when new educational programs are offered by Elsevier? *

Yes

Please provide us with suggestions for improving this activity.

Please provide details on any concerns or issues you had with this activity.

How did you hear about this symposium? Other...

Attestation to time spent on activity

The Elsevier Office of Continuing Medical Education designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credits^TM. I participated in this CME activity and claim ______ credits.

Credit hours *

Leave this field blank

Elsevier CME

Novel Therapeutic Approaches to Alzheimer’s Disease: A Focus on Immunotherapy

Evaluation

Evaluation

Course navigation

You are here

Novel Therapeutic Approaches to Alzheimer’s Disease: A Focus on Immunotherapy

Evaluation

Evaluation

Course navigation